Advanced Search

Study Preview



Study Title and Description

Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile.



Key Questions Addressed
1 How do different methods for detection of toxigenic C. difficile to assist with diagnosis of CDI compare in their sensitivity, specificity, and predictive values? a. Overall? b. Do performance measures vary with sample characteristics? c. Does testing strategy impact patient health or health system outcomes?
  • Comments Comments (
    0
    ) |
2 What are effective prevention strategies? a. What is the effectiveness of current prevention strategies? b. What are the harms associated with prevention strategies? c. How sustainable are prevention practices in health care (outpatient, hospital inpatient, extended care) and community settings?
  • Comments Comments (
    0
    ) |
3 What is the comparative effectiveness and harms of different antibiotic treatments? a. Does effectiveness vary by disease severity?
  • Comments Comments (
    0
    ) |
4 What are the effectiveness and harms of other interventions? a. Overall b. In patients with relapse/recurrent CDI.
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile.
Author Viala C., Le Monnier A., Maataoui N., Rousseau C., Collignon A., Poilane I.
Country Laboratoire de Microbiologie, Hôpital Jean Verdier, Assistance Publique - Hôpitaux de Paris, Bondy, France.
Year 2012
Numbers Pubmed ID: 22565213

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Detection, prevention, treatments, and efficacy and harms of interventions for C. difficile


Results & Comparisons

No Results found.